about

1

The goal is to work with partners to bring our drugs to the national and international markets, especially to bring more affordable,high-quality biologic medicines to patients.

Our leading pipeline is a next generation of anti-IgE antibody (LP-003), which is already in Phase III study, and prepare for BLA in 2025. The second leading pipeline is a bifunctional complement inhibitor (LP-005) , which is in Phase II at present.

Development
course